---
figid: PMC6855178__nihms-1058736-f0001
figtitle: Action of Targeted Therapies in Metastatic Renal Cell Carcinoma
organisms:
- Homo sapiens
- Mus musculus
- Bikinia letestui
- synthetic RNA
pmcid: PMC6855178
filename: nihms-1058736-f0001.jpg
figlink: /pmc/articles/PMC6855178/figure/F1/
number: F1
caption: 'Ligand binding of RTKs leads to many downstream effects. Proangiogenic RTKs
  (VEGFR, PDGFR, and FGFR) are labeled in blue, whereas growth factor ligand binding
  to RTKs is colored orange. Simplified mechanisms of the MAPK pathway (left) and
  mTOR pathway (right) are labeled in the tumor cell. Activation of HIF-α occurs in
  states of hypoxia and through lack of inhibition from a nonfunctional VHL gene.
  It leads to synthesis of VEGF, PDGF, and FGF. This can lead to MAPK activation in
  endothelial cells, depicted on the left side of the diagram. Through FKBP is the
  site of action of mTOR inhibitors everolimus and temsirolimus and is labeled in
  orange. Bevacizumab is a monoclonal antibody directed against VEGF. TKIs include
  sorafenib, sunitinib, axitinib, pazopanib, cabozantinib, and Ienvatinib. The aforementioned
  TKIs inhibit multiple RTKs. RTKs of importance are inhibited by the following TKIs:
  axitinib (VEGFR, PDGFR, c-KIT), sunitinib (VEGFR, PDGFR, RET, c-KIT), sorafenib
  (VEGFR, PDGFR, RET, c-KIT, Raf kinases), pazopanib (VEGFR, PDGFR, FGFR, c-KIT, RET),
  Ienvatinib (VEGFR, PDGFR, FGFR, c-KIT, RET), and cabozantinib (VEGFR, c-MET, AXL,
  c-KIT, RET).Abbreviations: ERK, extracellular signal-regulated kinase; FGF, fibroblast
  growth factor; FGFR, fibroblast growth factor receptor; FKBP, FK506-binding protein;
  GAS6, growth arrest-specific 6; HGF, hepatocyte growth factor; MAPK, mitogen-activated
  protein kinase; MEK, mitogen-activated protein kinase kinase; PDGF, platelet-derived
  growth factor; PDGFR, platelet-derived growth factor receptor; PI3K, phosphatidylinositol-3
  kinase; RTK, receptor tyrosine kinase; SCF, stem cell factor; TKI, tyrosine kinase
  inhibitor; VEGFR, VEGF receptor; VHL, von Hippel–Lindau.'
papertitle: Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
reftext: David M. Gill, et al. Am Soc Clin Oncol Educ Book. ;37:319-329.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9725982
figid_alias: PMC6855178__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC6855178__F1
ndex: fe8ffb77-debf-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6855178__nihms-1058736-f0001.html
  '@type': Dataset
  description: 'Ligand binding of RTKs leads to many downstream effects. Proangiogenic
    RTKs (VEGFR, PDGFR, and FGFR) are labeled in blue, whereas growth factor ligand
    binding to RTKs is colored orange. Simplified mechanisms of the MAPK pathway (left)
    and mTOR pathway (right) are labeled in the tumor cell. Activation of HIF-α occurs
    in states of hypoxia and through lack of inhibition from a nonfunctional VHL gene.
    It leads to synthesis of VEGF, PDGF, and FGF. This can lead to MAPK activation
    in endothelial cells, depicted on the left side of the diagram. Through FKBP is
    the site of action of mTOR inhibitors everolimus and temsirolimus and is labeled
    in orange. Bevacizumab is a monoclonal antibody directed against VEGF. TKIs include
    sorafenib, sunitinib, axitinib, pazopanib, cabozantinib, and Ienvatinib. The aforementioned
    TKIs inhibit multiple RTKs. RTKs of importance are inhibited by the following
    TKIs: axitinib (VEGFR, PDGFR, c-KIT), sunitinib (VEGFR, PDGFR, RET, c-KIT), sorafenib
    (VEGFR, PDGFR, RET, c-KIT, Raf kinases), pazopanib (VEGFR, PDGFR, FGFR, c-KIT,
    RET), Ienvatinib (VEGFR, PDGFR, FGFR, c-KIT, RET), and cabozantinib (VEGFR, c-MET,
    AXL, c-KIT, RET).Abbreviations: ERK, extracellular signal-regulated kinase; FGF,
    fibroblast growth factor; FGFR, fibroblast growth factor receptor; FKBP, FK506-binding
    protein; GAS6, growth arrest-specific 6; HGF, hepatocyte growth factor; MAPK,
    mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase;
    PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor;
    PI3K, phosphatidylinositol-3 kinase; RTK, receptor tyrosine kinase; SCF, stem
    cell factor; TKI, tyrosine kinase inhibitor; VEGFR, VEGF receptor; VHL, von Hippel–Lindau.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Vegfa
  - Gas6
  - Hgf
  - Met
  - Kitl
  - Pdgfrb
  - Kit
  - Ret
  - Axl
  - ras
  - Hras
  - Kras
  - Rem1
  - pk
  - Vhl
  - Zhx2
  - Mdk
  - Akt1
  - Fkbp1a
  - Ephb2
  - Mapk1
  - Mtor
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - GAS6
  - HGF
  - IL6
  - SOS1
  - KITLG
  - PDGFRB
  - PDGFRA
  - KDR
  - FLT1
  - FLT4
  - KIT
  - RET
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - AXL
  - MET
  - KRAS
  - HRAS
  - NRAS
  - VHL
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - HIF1A
  - EPAS1
  - HIF3A
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - Temsirolimus
  - Pazopanib
  - Lenvatinib
  - Cabozantinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
